Long-Term Outcomes in Puerto Ricans with Rheumatoid Arthritis (RA) Receiving Early Treatment with Disease-Modifying Anti-Rheumatic Drugs using the American College of Rheumatology Definition of Early RA

• Published in: The open rheumatology journal Vol. 11; no. 1; pp. 136 - 144
• Main Authors: Varela-Rosario, Noemí, Arroyo-Ávila, Mariangelí, Fred-Jiménez, Ruth M, Díaz-Correa, Leyda M, Pérez-Ríos, Naydi, Rodríguez, Noelia, Ríos, Grissel, Vilá, Luis M
• Format: Journal Article
• Language: English
• Published: United Arab Emirates Bentham Open 27.12.2017
• Subjects: Clinical Outcome; Early Treatment; Disease-Modifying anti-rheumatic drugs; Puerto Ricans; Rheumatoid arthritis; Hispanics
• ISSN: 1874-3129; 1874-3129
• DOI: 10.2174/1874312901711010136

Early treatment of rheumatoid arthritis (RA) results in better long-term outcomes. However, the optimal therapeutic window has not been clearly established. To determine the clinical outcome of Puerto Ricans with RA receiving early treatment with conventional and/or biologic disease-modifying anti-rheumatic drugs (DMARDs) based on the American College of Rheumatology (ACR) definition of early RA. A cross-sectional study was performed in a cohort of Puerto Ricans with RA. Demographic features, clinical manifestations, disease activity, functional status, and pharmacotherapy were determined. Early treatment was defined as the initiation of DMARDs (conventional and/or biologic) in less than 6 months from the onset of symptoms attributable to RA. Patients who received early (< 6months) and late (≥6 months) treatments were compared using bivariate and multivariate analyses. The cohort comprised 387 RA patients. The mean age at study visit was 56.0 years. The mean disease duration was 14.9 years and 337 (87.0%) patients were women. One hundred and twenty one (31.3%) patients received early treatment. In the multivariate analysis adjusted for age and sex, early treatment was associated with better functional status, lower probability of joint deformities, intra-articular injections and joint replacement surgeries, and lower scores in the physician's assessments of global health, functional impairment and physical damage of patients. Using the ACR definition of early RA, this group of patients treated with DMARDs within 6 months of disease had better long-term outcomes with less physical damage and functional impairment.